ஐ.எஸ்.எஸ்.என்: 2155-9880
Ata firouzi,Mohammad Javad Alemzadeh-Ansari,Zahra Khajali,Majid Maleki,Bahram Mohebbi,Sedigheh Saedi, MD; Zahra Hosseini*, MD; Parham Ostovan; Mohammadreza Baay; RaanaAsghari, Seyed Ehsan Parhizgar.
One of the rare complications of transcatheter closure of structural heart defects and recently advanced procedures in other conditions like valvular interventions, is intravascular subclinical and clinical hemolysis. The accurate incidence, etiology, management and approach to these patients are not really known. In this retrospective, mono-centric study, we recruited all the patients who underwent the transcatheter closure of atrial septal defects (ASDs), patent foramen ovales (PFOs), ventricular septal defects (VSDs), patent ductus arteriosus (PDAs), sinus of Valsalva ruptures (SVRs) and paravalvular leakages (PVLs) in the time period between 2017 and 2019. We evaluated the incidence and our approach to management (either conservative or invasive approaches) of this infrequent side effects among 675 patients in this time period.